BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 31430398)

  • 1. At the bench: Engineering the next generation of cancer vaccines.
    Shae D; Baljon JJ; Wehbe M; Becker KW; Sheehy TL; Wilson JT
    J Leukoc Biol; 2020 Oct; 108(4):1435-1453. PubMed ID: 31430398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Changing Landscape of Therapeutic Cancer Vaccines-Novel Platforms and Neoantigen Identification.
    Jou J; Harrington KJ; Zocca MB; Ehrnrooth E; Cohen EEW
    Clin Cancer Res; 2021 Feb; 27(3):689-703. PubMed ID: 33122346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
    Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
    Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy.
    Lee KL; Benz SC; Hicks KC; Nguyen A; Gameiro SR; Palena C; Sanborn JZ; Su Z; Ordentlich P; Rohlin L; Lee JH; Rabizadeh S; Soon-Shiong P; Niazi K; Schlom J; Hamilton DH
    Cancer Immunol Res; 2019 Aug; 7(8):1359-1370. PubMed ID: 31292145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amplified Cancer Immunotherapy of a Surface-Engineered Antigenic Microparticle Vaccine by Synergistically Modulating Tumor Microenvironment.
    Zhao H; Zhao B; Wu L; Xiao H; Ding K; Zheng C; Song Q; Sun L; Wang L; Zhang Z
    ACS Nano; 2019 Nov; 13(11):12553-12566. PubMed ID: 31689085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alteration of the Tumor Stroma Using a Consensus DNA Vaccine Targeting Fibroblast Activation Protein (FAP) Synergizes with Antitumor Vaccine Therapy in Mice.
    Duperret EK; Trautz A; Ammons D; Perales-Puchalt A; Wise MC; Yan J; Reed C; Weiner DB
    Clin Cancer Res; 2018 Mar; 24(5):1190-1201. PubMed ID: 29269377
    [No Abstract]   [Full Text] [Related]  

  • 7. Methods for improving the immunogenicity and efficacy of cancer vaccines.
    Pilla L; Ferrone S; Maccalli C
    Expert Opin Biol Ther; 2018 Jul; 18(7):765-784. PubMed ID: 29874943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In situ antitumor vaccination: Targeting the tumor microenvironment.
    Li H; Yu J; Wu Y; Shao B; Wei X
    J Cell Physiol; 2020 Jul; 235(7-8):5490-5500. PubMed ID: 32030759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in Therapeutic Cancer Vaccines.
    Wong KK; Li WA; Mooney DJ; Dranoff G
    Adv Immunol; 2016; 130():191-249. PubMed ID: 26923002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes.
    Jeanbart L; Ballester M; de Titta A; Corthésy P; Romero P; Hubbell JA; Swartz MA
    Cancer Immunol Res; 2014 May; 2(5):436-47. PubMed ID: 24795356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current challenges for cancer vaccine adjuvant development.
    Bowen WS; Svrivastava AK; Batra L; Barsoumian H; Shirwan H
    Expert Rev Vaccines; 2018 Mar; 17(3):207-215. PubMed ID: 29372660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic cancer vaccines: From initial findings to prospects.
    Song Q; Zhang CD; Wu XH
    Immunol Lett; 2018 Apr; 196():11-21. PubMed ID: 29407608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-Specific T Cell Activation in Malignant Brain Tumors.
    Mohme M; Neidert MC
    Front Immunol; 2020; 11():205. PubMed ID: 32117316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical and clinical development of neoantigen vaccines.
    Li L; Goedegebuure SP; Gillanders WE
    Ann Oncol; 2017 Dec; 28(suppl_12):xii11-xii17. PubMed ID: 29253113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses.
    Vermaelen K
    Front Immunol; 2019; 10():8. PubMed ID: 30723469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium.
    Guo Y; Chen Y; Liu X; Min JJ; Tan W; Zheng JH
    Cancer Lett; 2020 Jan; 469():102-110. PubMed ID: 31666180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic cancer vaccines.
    Saxena M; van der Burg SH; Melief CJM; Bhardwaj N
    Nat Rev Cancer; 2021 Jun; 21(6):360-378. PubMed ID: 33907315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational Design of T-Cell- and B-Cell-Based Therapeutic Cancer Vaccines.
    Li WH; Su JY; Li YM
    Acc Chem Res; 2022 Sep; 55(18):2660-2671. PubMed ID: 36048514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemical Strategies to Boost Cancer Vaccines.
    Li WH; Li YM
    Chem Rev; 2020 Oct; 120(20):11420-11478. PubMed ID: 32914967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside.
    Roy S; Sethi TK; Taylor D; Kim YJ; Johnson DB
    J Leukoc Biol; 2020 Oct; 108(4):1455-1489. PubMed ID: 32557857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.